

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	SRF IN
Equity Shares (m)	296
M.Cap.(INRb)/(USDb)	897.5 / 10.2
52-Week Range (INR)	3325 / 2127
1, 6, 12 Rel. Per (%)	3/-7/28
12M Avg Val (INR M)	1691

Financials & Valuations (INR b)

Y/E Mar	2026E	2027E	2028E
Sales	163.5	194.1	217.6
EBITDA	37.1	47.8	54.2
PAT	20.3	27.3	31.4
EBITDA (%)	22.7	24.6	24.9
EPS (INR)	68.1	91.8	105.7
EPS Gr. (%)	47.9	34.7	15.1
BV/Sh. (INR)	475	550	638

Ratios

Net D/E	0.3	0.3	0.2
RoE (%)	15.2	17.9	17.8
RoCE (%)	12.4	14.8	15.0
Payout (%)	25.2	18.5	16.1

Valuations

P/E (x)	44.4	33.0	28.7
EV/EBITDA (x)	25.3	19.7	17.3
Div Yield (%)	0.6	0.6	0.6
FCF Yield (%)	0.5	0.7	1.4

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	50.3	50.3	50.3
DII	19.6	18.9	17.8
FII	18.0	18.2	18.3
Others	12.2	12.6	13.7

Note: FII includes depository receipts

CMP: INR3,028 TP: INR3,650 (+21%) Buy

Chemical and PFF continue to support operating performance In-line 2QFY26

- SRF delivered a strong 2QFY26, with EBIT surging 55% YoY, fueled by a robust 96%/44% YoY jump in the chemicals/performance films & foil (PFF) businesses, despite ongoing global headwinds. However, the technical textiles business EBIT declined 41% YoY in 2Q.
- The chemical business (specialty chemicals and fluorochemicals segments) is expected to deliver a stronger 2H performance due to seasonality, new product traction, and a stable-to-better pricing outlook for refrigerants. The company expects its chemical revenue growth to surpass 20% in FY26.
- We broadly retain our FY26/FY27/FY28 EBITDA estimates and **reiterate our BUY rating**. We value the stock on an SoTP basis to arrive at our **TP of INR3,650**.

Operating efficiency and better product mix fuel margin expansion

- SRF reported an overall revenue of INR36.4b (est. INR38.8b) in 2QFY26, up ~6% YoY. EBITDA margin expanded 570bp YoY to 22.1% (est. of 21.2%). EBITDA stood at INR8b (est. in line), up 44% YoY. Adj. PAT grew 87% YoY to INR4.2b (est. in line), adjusted for a forex loss of INR306m in 2QFY26.
- **The chemical segment's** revenue (46%/74% of total sales/EBIT in 2Q) grew 23% YoY to INR16.7b, while EBIT grew 96% YoY to INR4.8b. EBIT margin was 28.9% (vs. 18.1% in 2QFY25). The fluorochemicals business achieved record refrigerant sales and benefited from higher prices, while the specialty chemicals business saw volume growth and positive traction from new product launches. Efficiency measures across both segments improved overall margins.
- **PFF** revenue (39%/18% of total sales/EBIT in 2QFY26) declined marginally by 1% YoY to INR14.b, while EBIT grew ~44% YoY to INR1.2b. Margin expanded 260bp YoY to 8.4% during the quarter. The packaging films business achieved margin growth in its value-added product segment while SRF maintained its status as the leading exporter of BOPET films in India.
- **Technical textiles'** revenue (13%/7% of total sales/EBIT in 2QFY26) was down 11% YoY to INR4.7b. EBIT dipped 41% YoY to INR423m. EBIT margin contracted 440bp YoY to 8.9%. The technical textiles business faced significant headwinds due to aggressive import pricing of nylon tyre cord fabrics and belting fabrics from China and low demand for polyester industrial yarn.
- In 1HFY26, SRF's revenue/EBITDA/adj. PAT grew 8%/38%/71% YoY to INR74.6b/INR16.3b/INR8.4b. while EBITDA margin expanded 460bp to 21.8%. Gross debt stood at INR45.3b vs. INR46.4b in Mar'25. SRF generated operating cash flow of ~INR10b.

Highlights from the management commentary

- **Guidance:** SRF guided over 20% revenue growth for the chemicals business in FY26, driven by a strong 1H. This is despite some order deferment (for older products) from large global agro players to the later part of 2HFY26.

Research Analyst: **Sumant Kumar** (Sumant.Kumar@MotilalOswal.com) | **Meet Jain** (Meet.Jain@MotilalOswal.com)

Research Analyst: **Nirvik Saini** (Nirvik.Saini@MotilalOswal.com) | **Yash Darak** (Yash.darak@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **Fluorochemicals:** SRF entered into strategic agreements with The Chemours Company for manufacturing, supply, and distribution of select fluoropolymers and fluoroelastomers. A notable portion of production will cater to Chemours' requirements, generating substantial revenue for SRF. The project will be commissioned in phases, with final completion expected by Dec'26.
- **Capex:** SRF will be incurring ~INR22-23b of capex in FY26. The Board also enhanced its capex outflow for fluoropolymers to INR7.45b from INR5.95b to accommodate the expanded project scope. Of this, ~INR4b will be for non-Chemours products, and the balance of INR2.95b will be for two products of Chemours.

Valuation and view

- We expect the chemicals business (fluorochemicals and specialty chemicals) to witness higher growth momentum in 2HFY26 (vs. 1HFY26), fueled by 1) the ramp-up of recently commissioned plants, 2) the launch of new products, 3) a strong R&D and innovation pipeline, 4) stable demand for refrigerant gases, and 5) a diversified portfolio.
- The packaging business is also likely to report better margins driven by higher realizations of BOPP, a strong portfolio of high-impact, value-added products, and the anti-dumping duty on Chinese aluminum foil imports to India.
- We build in a revenue/EBITDA/Adj. PAT CAGR of 14%/24%/32% over FY25-28E. We broadly maintain our FY26/FY27/FY28 EBITDA estimates and **reiterate our BUY rating**. We value the stock on an SoTP basis to arrive at our **TP of INR3,650**.

Consolidated - Quarterly Earnings Model

(INR m)


Y/E March	FY25				FY26				FY25	FY26E	FY25E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2Q	%
Net Sales	34,641	34,243	34,913	43,133	38,186	36,402	39,828	49,120	1,46,931	1,63,537	38,840	-6
YoY Change (%)	3.8	7.8	14.4	20.8	10.2	6.3	14.1	13.9	11.8	11.3	13.4	
Total Expenditure	28,435	28,637	28,375	33,108	29,975	28,354	31,520	36,594	1,18,555	1,26,443	30,593	
EBITDA	6,207	5,606	6,538	10,025	8,212	8,048	8,308	12,526	28,376	37,093	8,247	-2
Margins (%)	17.9	16.4	18.7	23.2	21.5	22.1	20.9	25.5	19.3	22.7	21.2	
Depreciation	1,882	1,939	1,943	1,952	2,032	2,121	2,100	2,311	7,715	8,565	2,040	
Interest	965	938	963	894	799	707	750	800	3,760	3,056	895	
Other Income	253	333	396	345	291	257	375	436	1,327	1,360	365	
PBT before EO expense	3,612	3,063	4,029	7,525	5,671	5,477	5,833	9,851	18,229	26,832	5,677	
Extra-Ord expense & DO	172	226	342	451	-87	306	0	0	1,192	219	0	
PBT	3,440	2,837	3,687	7,074	5,758	5,171	5,833	9,851	17,037	26,613	5,677	
Tax	918	822	976	1,813	1,435	1,289	1,429	2,414	4,529	6,567	1,391	
Rate (%)	25.4	26.9	24.2	24.1	25.3	23.5	24.5	24.5	24.8	24.5	24.5	
Reported PAT	2,522	2,014	2,711	5,261	4,323	3,882	4,404	7,437	12,508	20,046	4,286	
Adj PAT	2,695	2,240	3,053	5,712	4,236	4,188	4,404	7,437	13,700	20,265	4,286	-2
YoY Change (%)	-29.6	-30.0	12.4	30.4	57.2	87.0	44.3	30.2	-3.0	47.9	91	
Margins (%)	7.8	6.5	8.7	13.2	11.1	11.5	11.1	15.1	9.3	12.4	11.0	

Key Performance Indicators

Y/E March	FY25				FY26		FY25	FY26E
Consolidated	1Q	2Q	3Q	4Q	1Q	2Q		
Segment Revenue (INRm)								
Technical Textile	5,253	5,355	5,098	4,584	4,666	4,743	20,291	18,658
Chemicals	14,820	13,578	14,957	23,553	18,390	16,669	66,908	81,270
Packaging Film	13,363	14,206	13,848	14,122	14,182	14,081	55,538	59,722
Others	1,262	1,128	1,011	874	949	908	4,275	3,887
Segment Revenue Growth (%)								
Technical Textile	13.1	5.8	11.2	-2.2	-11.2	-11.4	6.9	-8.0
Chemicals	-10.8	-4.8	7.3	29.7	24.1	22.8	6.3	21.5
Packaging Film	22.1	26.7	27.0	19.4	6.1	-0.9	23.7	7.5
Other	6.3	-11.1	-10.9	-17.6	-24.8	-19.5	-8.1	-9.1
Segment Results (INRm)								
Technical Textile	677	713	589	401	376	423	2,381	1,675
Chemicals	3,064	2,461	3,638	7,485	5,029	4,813	16,648	23,912
Packaging Film	868	828	904	1,046	1,402	1,190	3,645	5,500
Others	236	172	157	124	134	75	688	514
Segment EBIT Margins (%)								
Technical Textile	12.9	13.3	11.6	8.7	8.1	8.9	11.7	9.0
Chemicals	20.7	18.1	24.3	31.8	27.3	28.9	24.9	29.4
Packaging Film	6.5	5.8	6.5	7.4	9.9	8.4	6.6	9.2
Others	18.7	15.2	15.5	14.2	14.1	8.3	16.1	13.2
Cost Break-up								
RM Cost (% of sales)	52.7	53.6	51.7	51.8	50.0	48.6	52.4	50.1
Staff Cost (% of sales)	7.3	7.4	7.5	6.4	7.3	7.6	7.1	6.8
Power and Fuel Cost (% of sales)	9.9	10.1	9.5	7.7	9.5	9.4	9.2	9.0
Other Cost (% of sales)	12.2	12.6	12.6	10.9	11.7	12.3	12.0	11.4
Gross Margins (%)	47.3	46.4	48.3	48.2	50.0	51.4	47.6	49.9
EBITDA Margins (%)	17.9	16.4	18.7	23.2	21.5	22.1	19.3	22.7
EBIT Margins (%)	12.5	10.7	13.2	18.7	16.2	16.3	14.1	17.4


Key Exhibits

Exhibit 1: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 2: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 3: Consolidated adjusted PAT trend




Source: Company, MOFSL

Exhibit 4: Revenue mix trend




Source: Company, MOFSL

Exhibit 5: EBIT mix trend




Source: Company, MOFSL

Exhibit 6: Revenue trend in the Chemical business




Source: Company, MOFSL

Exhibit 7: EBIT trend in the Chemical business




Source: Company, MOFSL

Exhibit 8: Revenue trend in the Packaging Film business




Source: Company, MOFSL

Exhibit 9: EBIT trend in the Packaging Film business




Source: Company, MOFSL

Exhibit 10: Revenue trend in the Technical Textiles business



Source: Company, MOFSL

Exhibit 11: EBIT trend in the Technical Textiles business



Source: Company, MOFSL



Key highlights from the management commentary

Chemicals business: Specialty chemicals

- Specialty Chemicals Business performance improved compared to last year, driven by higher volumes and operational efficiencies through cost, process optimization, and favorable product mix.
- Recently launched products continued to show positive traction
- The management anticipates the robust product pipeline to accelerate future growth momentum.
- SRF launched one new Active Ingredient (AI) along with three new Agro and one new Pharma product during 1HFY26.
- Product funnel remains strong, with several new Pharma intermediates and Agro AI opportunities under development.
- The new Odisha site is set to house future Chemical facilities, strengthening SRF's manufacturing footprint and supporting long-term capacity expansion.
- Agro majors have deferred procurement to the late 2HFY26 amid delayed demand from customers.
- Market dynamics are currently being shaped by sustained Chinese competition and uncertainty surrounding US tariffs.
- Raw material prices appear to have bottomed out
- The agrochemicals segment is expected to pick up gradually
- SRF continues to collaborate with global innovators on complex molecules, reaffirming SRF R&D leadership in delivering sophisticated solutions.
- Historically, 2H has always been stronger than 1H.
- Export stood at 65-66% of the revenue in 2QFY26
- Full-year growth guidance of specialty chemicals remains on track to surpass the 20% growth as previously guided, despite some deferment of demand seen in this space.

Chemical: Fluorochemicals

- The fluorochemicals business delivered a strong YoY performance driven by higher volumes and realizations of HFCs across key products.
- While some sequential softness in volumes was observed in the domestic market due to seasonality and an overall lower rack market, the business continued to demonstrate resilience by enhancing its export sales amid an uncertain global environment.
- SRF maintained its leadership in domestic RAC and MAC markets
- Thailand and the Middle East markets continued to perform well
- SRF entered into strategic agreements with The Chemours Company for manufacturing, supply, and distribution of certain fluoropolymers and fluoroelastomers, with the capex cost now enhanced to INR7.45b from INR5.95b. The project will be executed in phases and is expected to be completed by December 2026.
- The company is getting into newer products, which were not planned earlier. Of this INR4.50b is one of the products, which is a non-Chemours product, and the balance capex is for two products that are of Chemours.

- The rationale behind the Chemours deal lies in partnering with a global player to expand the company's fluoropolymer business and strengthen its presence in products that have a global market reach rather than being limited to localized segments.
- A large part of the production will be sold to Chemours for their requirement, while the Revenue from this agreement is expected to be fairly large
- Global HFC prices continue to remain firm, driven by China's quota-led supply restrictions and steady international demand.
- Management anticipates the domestic ref gas demand to recover in 2HFY26 after a weak 1H due to prolonged monsoons.
- The HFO project is expected to be commissioned in FY27, and revenue will start from FY28.
- The company wants to operate the plant at maximum capacity possible to avail a higher quota. SRF will end FY26 at maximum capacity.
- Export in 2QFY26 stood at 60%.
- Prices of R22 have been range-bound. Over the last 2-3 quarters, the price momentum has been positive.
- SRF aims to end FY26 at maximum capacity for HFCs, with the specialty chemicals business to be the key growth driver

PFF business

- The packaging film business achieved stable revenue in 2QFY26 with a higher margin compared to 2QFY25, led by higher volumes and realization for BOP and the ramp-up of production and sales of Aluminum foil; supported by higher realization in both the domestic and export markets.
- Improved performance in Thailand and Hungary, though competition from cheaper imports supported the growth of the segment
- Sequential softness reflected in weak demand and prices for BOPE
- SRF maintained its position as India's largest BOPET exporter
- The global supply for BOPET continues to exceed
- The Anti-dumping duty on Chinese aluminum foil imports in India supported better realizations and improved pricing stability demand.
- Chinese suppliers continue aggressive pricing in Southeast Asian markets
- GST 2.0 reforms implemented during the quarter seemed to have a short-term impact. Due to reprinting, repackaging, and resizing, the business remains focused on scaling, value-added products and sustainable structures
- There was some impact of the US tariff on the PFF segment, and SRF has taken countermeasures such as shifting some US demand to the Thailand unit.

Technical textiles business:

- The performance was adversely impacted by a weak market, with the Nylon Tyre Cord Fabric (NTCF) and Belting Fabric (BF) margin under pressure due to Chinese imports
- Demand for Polyester Industrial Yarn (PIY) remained soft due to the prolonged monsoons.
- The new Belting fabric capacity ramping up is expected to contribute to higher volumes in 2HFY26.
- SRF maintained its market share in NTCF as well as BF.

- Market conditions remained challenging due to cheap imports from China
- US import tariffs negatively impacted Belting Fabric, leading to increased imports from China at significantly lower prices.
- The management anticipates the market to improve in 2HFY26, supported by recovery in the automotive and industrial sectors post GST 2.0.

Other

- SRF continued to maintain a leadership position in the domestic market, both in volume and price, in the coated fabrics segment.
- SRF retained price leadership in the laminated fabrics market, backed by consistently strong on-time customer deliveries.
- R&D team, comprising of over 450 professionals, is focused on developing complex chemistries and advanced applications.
- SRF now holds 153 patents and has filed 501 process patents. R&D remains at the core of the strategy, enabling process development, scale-up up and commercialization across agrochemicals, pharmaceuticals.
- However, weakening of INR against USD and Euro has hit the overall 2Q results, with global interest rate cycles trending downwards, management anticipates further reduction in the borrowing costs in the near future.
- CFO will step down to pursue other opportunities. The company is in the process of identifying my successor and will ensure a smooth transition to maintain continuity and uphold its commitment to financial discipline and long-term value creation.
- The company plans to incur a capex of around INR22b-INR23b (including the Odisha land parcel ~INR2.82b) in FY26.

Valuation and view

- We expect the chemicals business (fluorochemicals and specialty chemicals) to witness higher growth momentum in 2HFY26 (vs. 1HFY26), fueled by 1) the ramp-up of recently commissioned plants, 2) the launch of new products, 3) a strong R&D and innovation pipeline, 4) stable demand for refrigerant gases, and 5) a diversified portfolio.
- The packaging business is also likely to report better margins driven by higher realizations of BOPP, a strong portfolio of high-impact, value-added products, and the anti-dumping duty on Chinese aluminum foil imports to India.
- We build in a revenue/EBITDA/Adj. PAT CAGR of 14%/24%/32% over FY25-28E. We broadly maintain our FY26/FY27/FY28 EBITDA estimates and **reiterate our BUY rating**. We value the stock on an SoTP basis to arrive at our **TP of INR3,650**.

Exhibit 12: Our valuation methodology

EV/EBITDA	FY27 EBITDA (INRm)	Multiple (x)	EV (INRm)
Technical Textiles	4,180	12	52,043
Chemicals	35,534	27	9,75,195
Packaging Films	10,303	12	1,28,070
Others	1,031	10	10,722
Less: Other Income/Unallocable Expenses	3,229	10	32,285
Total EV			11,33,745
Less: Debt			50,412
Less: Minority Interest			-
Add: Cash & Cash Equivalents			2,303
Target Mcap (INR m)			10,85,636
Outstanding Share (m)			297.4
TP (INR)			3,650

Source: MOFSL

Exhibit 13: Revisions to our estimates

Earnings Change (INR m)	Old			New			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	1,65,975	1,97,031	2,20,833	1,63,537	1,94,125	2,17,595	-1	-1	-1
EBITDA	38,001	48,423	54,860	37,093	47,820	54,187	-2	-1	-1
Adj. PAT	20,670	27,853	32,042	20,265	27,304	31,426	-2	-2	-2

Source: MOFSL

Financials and valuations

Consolidated - Income Statement								(INRm)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Income from Operations	84,000	1,24,337	1,48,703	1,31,385	1,46,931	1,63,537	1,94,125	2,17,595
Less: Excise Duty	0	0	0	0	0	0	0	0
Total Income from Operations	84,000	1,24,337	1,48,703	1,31,385	1,46,931	1,63,537	1,94,125	2,17,595
Change (%)	16.5	48.0	19.6	-11.6	11.8	11.3	18.7	12.1
Cost of Materials Consumed	40,189	60,669	73,935	67,088	76,992	81,979	95,810	1,06,808
Personnel Expenses	6,214	7,800	8,138	9,350	10,425	11,124	12,230	13,709
Other Expenses	16,264	24,835	30,297	28,339	31,138	33,341	38,266	42,892
Total Expenditure	62,667	93,305	1,12,371	1,04,777	1,18,555	1,26,443	1,46,305	1,63,409
% of Sales	74.6	75.0	75.6	79.7	80.7	77.3	75.4	75.1
EBITDA	21,333	31,032	36,332	26,608	28,376	37,093	47,820	54,187
Margin (%)	25.4	25.0	24.4	20.3	19.3	22.7	24.6	24.9
Depreciation	4,531	5,172	5,753	6,726	7,715	8,565	9,759	11,245
EBIT	16,803	25,860	30,579	19,882	20,661	28,528	38,061	42,942
Int. and Finance Charges	1,340	1,159	2,048	3,023	3,760	3,056	3,459	3,114
Other Income	545	428	749	830	1,327	1,360	1,564	1,798
PBT bef. EO Exp.	16,008	25,128	29,280	17,689	18,229	26,832	36,166	41,625
EO Items	116	727	-1,040	-767	-1,192	-219	0	0
PBT after EO Exp.	16,123	25,856	28,240	16,922	17,037	26,613	36,166	41,625
Current Tax	4,154	7,139	6,617	3,565	4,544	6,567	8,862	10,199
Deferred Tax	-10	-173	0	0	-14	0	0	0
Tax Rate (%)	25.7	26.9	23.4	21.1	26.6	24.7	24.5	24.5
Less: Minority Interest	0	0	0	0	0	0	0	0
Reported PAT	11,979	18,889	21,623	13,357	12,508	20,046	27,304	31,426
Adjusted PAT	11,864	18,162	22,663	14,124	13,700	20,265	27,304	31,426
Change (%)	29.0	53.1	24.8	-37.7	-3.0	47.9	34.7	15.1
Margin (%)	14.1	14.6	15.2	10.8	9.3	12.4	14.1	14.4

Consolidated - Balance Sheet								(INRm)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	603	2,974	2,974	2,974	2,974	2,974	2,974	2,974
Total Reserves	67,962	82,679	1,00,296	1,11,816	1,23,288	1,38,277	1,60,525	1,86,894
Net Worth	68,564	85,654	1,03,271	1,14,790	1,26,262	1,41,251	1,63,499	1,89,869
Minority Interest	0	0	0	0	0	0	0	0
Deferred Liabilities	3,862	6,775	8,092	9,387	10,553	10,553	10,553	10,553
Total Loans	33,950	35,394	43,541	49,202	46,412	48,412	50,412	45,412
Capital Employed	1,06,376	1,27,822	1,54,903	1,73,380	1,83,227	2,00,217	2,24,464	2,45,834
Gross Block	96,167	1,06,943	1,28,622	1,67,373	1,80,146	2,00,146	2,33,146	2,66,146
Less: Accum. Deprn.	20,071	25,243	30,997	37,723	45,438	54,003	63,761	75,006
Net Fixed Assets	76,096	81,699	97,626	1,29,650	1,34,708	1,46,143	1,69,384	1,91,139
Goodwill on Consolidation	6	0	0	0	0	0	0	0
Capital WIP	7,723	16,716	24,055	8,053	8,110	13,110	8,110	3,110
Current Investments	4,125	3,167	4,901	4,056	7,045	7,045	7,045	7,045
Total Investments	4,167	3,209	4,942	5,267	8,273	8,273	8,273	8,273
Curr. Assets, Loans&Adv.	41,121	56,025	60,735	61,574	64,123	66,521	77,613	86,574
Inventory	14,658	21,385	22,743	23,265	23,490	24,257	28,349	31,603
Account Receivables	12,746	17,925	17,856	19,428	21,695	22,402	26,593	29,808
Cash and Bank Balance	2,820	4,594	6,165	4,075	3,538	2,151	2,303	1,740
Loans and Advances	10,898	12,123	13,972	14,805	15,401	17,711	20,368	23,423
Curr. Liability & Prov.	22,918	29,944	32,642	31,440	32,344	34,188	39,273	43,620
Account Payables	15,852	20,964	22,313	21,978	23,316	24,257	28,349	31,603
Other Current Liabilities	6,544	8,391	9,642	8,660	8,104	8,914	9,806	10,786
Provisions	522	590	687	802	924	1,017	1,118	1,230
Net Current Assets	18,203	26,081	28,093	30,134	31,779	32,333	38,340	42,954
Deferred Tax assets	181	116	187	276	357	357	357	357
Appl. of Funds	1,06,376	1,27,822	1,54,903	1,73,380	1,83,227	2,00,217	2,24,464	2,45,834

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)								
EPS	39.9	61.1	76.2	47.5	46.1	68.1	91.8	105.7
Cash EPS	55.1	78.5	95.5	70.1	72.0	96.9	124.6	143.5
BV/Share	230.5	288.0	347.2	385.9	424.5	474.9	549.7	638.3
DPS	4.9	16.8	7.2	7.2	15.0	17.0	17.0	17.0
Payout (%)	12.1	26.4	9.9	16.0	35.7	25.2	18.5	16.1
Valuation (x)								
P/E	76	50	40	64	66	44	33	29
Cash P/E	55	39	32	43	42	31	24	21
P/BV	13	11	9	8	7	6	6	5
EV/Sales	11	7	6	7	6	6	5	4
EV/EBITDA	43	30	26	35	33	25	20	17
Dividend Yield (%)	0.2	0.6	0.2	0.2	0.5	0.6	0.6	0.6
FCF per share	19.1	9.7	0.0	-6.1	40.5	15.9	22.4	42.4
Return Ratios (%)								
RoE	20.1	23.6	24.0	13.0	11.4	15.2	17.9	17.8
RoCE	13.4	17.2	17.9	10.5	9.6	12.4	14.8	15.0
RoIC	26.3	34.2	34.7	18.2	17.4	21.9	25.8	25.4
Working Capital Ratios								
Fixed Asset Turnover (x)	0.9	1.2	1.2	0.8	0.8	0.8	0.8	0.8
Asset Turnover (x)	0.8	1.0	1.0	0.8	0.8	0.8	0.9	0.9
Inventory (Days)	133	129	112	127	111	108	108	108
Debtor (Days)	55	53	44	54	54	50	50	50
Creditor (Days)	144	126	110	120	111	108	108	108
Working Cap. Turnover (Days)	67	63	54	72	70	67	68	69
Leverage Ratio (x)								
Current Ratio	1.8	1.9	1.9	2.0	2.0	1.9	2.0	2.0
Interest Cover Ratio	13	22	15	7	5	9	11	14
Debt/Equity	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.2

Consolidated - Cash Flow Statement

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
(INRm)								
OP/(Loss) before Tax	16,099	25,856	28,240	16,922	17,037	26,613	36,166	41,625
Depreciation	4,531	5,172	5,753	6,726	7,715	8,565	9,759	11,245
Interest & Finance Charges	1,340	1,159	2,048	3,023	3,760	3,056	3,459	3,114
Direct Taxes Paid	-2,553	-4,016	-6,617	-3,565	-4,544	-6,567	-8,862	-10,199
(Inc)/Dec in WC	-1,236	-6,645	-408	-2,168	906	-1,941	-5,854	-5,178
CF from Operations	18,181	21,527	29,017	20,938	24,875	29,725	34,668	40,608
Others	-464	-469	0	0	0	0	0	0
CF from Operating incl EO	17,717	21,057	29,017	20,938	24,875	29,725	34,668	40,608
(inc)/dec in FA	-12,047	-18,171	-29,019	-22,748	-12,830	-25,000	-28,000	-28,000
Free Cash Flow	5,670	2,886	-2	-1,810	12,044	4,725	6,668	12,608
(Pur)/Sale of Investments	-1,886	1,028	-1,733	-325	-3,006	0	0	0
Others	-1,064	1,265	1,138	800	996	0	0	0
CF from Investments	-14,997	-15,877	-29,614	-22,273	-14,840	-25,000	-28,000	-28,000
Issue of Shares	7,500	2	0	0	0	0	0	0
Inc/(Dec) in Debt	-6,856	622	8,147	5,662	-2,790	2,000	2,000	-5,000
Interest Paid	-1,574	-1,173	-2,048	-3,023	-3,760	-3,056	-3,459	-3,114
Dividend Paid	-1,408	-2,117	-2,142	-2,142	-4,462	-5,056	-5,056	-5,056
Others	1,182	-741	-1,789	-1,252	439	0	0	0
CF from Fin. Activity	-1,155	-3,406	2,168	-754	-10,572	-6,112	-6,515	-13,171
Inc/Dec of Cash	1,565	1,774	1,571	-2,089	-538	-1,387	153	-563
Opening Balance	1,255	2,820	4,594	6,164	4,075	3,538	2,151	2,303
Closing Balance	2,820	4,594	6,164	4,075	3,538	2,151	2,303	1,740

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may: (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj

Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.